ARCHIVES

Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction.

This article is from The Cancer Letter archive.

Vol. 32 No. 15 | April 21, 2006

Download PDF Visit The Full Archive

Related Articles

Agency Asks GnRH Sponsors To Add Warnings On Labels

October 22, 2010

“Leadership Vacuum: At NCI Allows NIH To Look At Reorganization, Varmus Says

November 4, 1994

Brachytherapy Prevents Endometrial Cancer Return

June 27, 2008

In Brief: Steve Carter Accepts Job With Bristol, Phillips Elected NCG Chairman; Murray Copeland Dies

April 9, 1982

NCI Cooperative Groups Begin Trial Of Individualized Rx For Breast Cancer

May 26, 2006

NCI SBIR Offers $10 million in 10 Awards

February 18, 2011